SVSara Valencia

Sara Valencia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sara Valencia has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Associations Between Attention-Deficit/Hyperactivity Disorder Stimulant Medications and Irritable Bowel Syndrome

    by Sarah Kim, Jack Loesch, Elizabeth J. Short, Prashant Singh, Li Tang, Jaime Pérez, Madison Simons, Eyad Hamza, Sara Valencia, Trisha Pasricha, et al.

    INTRODUCTION: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction affecting 11% of the global population. Patients with attention-deficit/hyperactivity disorder (ADHD) have increased odds of IBS, but this may be confounded by stimulant use. The present study examined the association between ADHD and subsequent IBS, comparing ADHD patients treated with stimulants to those who were unmedicated. METHODS: This retrospective cohort study used the TriNetX U.S. Collaborative Network, a multi-institutional electronic health record platform with de-identified data from 117 million patients across 71 U.S. healthcare organizations. Adults with ADHD were divided into those who had ever received stimulants (stimulant cohort) or never received ADHD medications (“control cohort”). The primary outcome was a diagnostic record of IBS any time after the index event. IBS with Constipation (IBS-C), IBS with diarrhea, and mixed IBS were assessed separately. Cohorts were propensity score matched for demographics, comorbidities, and behavioral factors. Odds ratios (OR) with 95% confidence intervals (CI) were calculated. RESULTS: In the stimulant cohort, 2,104 of 112,832 patients (1.9%) received an IBS diagnosis versus 2,333 of 112,506 patients (2.1%) in the control cohort. Stimulant exposure was associated with a 10.3% decreased risk of any IBS (OR, 0.90; 95% CI, 0.85–0.95) and a 14.1% decreased risk for IBS-C (OR, 0.86; 95% CI, 0.74–0.99). DISCUSSION: Stimulant exposure was associated with a decreased risk of IBS and IBS-C. This supports the view among ADHD researchers that stimulants are effective and low-risk treatments. Future studies using longitudinal or prospective data are needed to validate these findings.

  • Open Access

    Adenoma and Sessile Serrated Polyp Detection Rates in Adults Using Glucagon-Like Peptide-1 Receptor Agonists

    by Samita Garg, Din Hoxha, David Long, Sara Valencia, Qijun Yang, Anthony Lembo, John J. Vargo, Dian-Jung Chiang

    INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are increasingly used for managing diabetes and obesity. Although they improve glycemic control, they also delay gastrointestinal motility, potentially leading to inadequate bowel preparation for colonoscopy, which can increase the risk of missed lesions. This study aimed to evaluate the impact of GLP-1RA use on the quality of bowel preparation and on adenomas and sessile serrated polyp (SSP) detection. METHODS: We conducted a retrospective cohort study of outpatient screening and surveillance colonoscopies at a tertiary academic medical center. Adults who used a GLP-1RA within 1 week of their colonoscopy formed the treatment group; patients not on GLP-1RA (nonusers) who never used GLP-1RA served as controls. Propensity score weighting was applied for age, sex, BMI, race, diabetes status, and relevant medications. The subgroup analysis was stratified based on diabetes status and GLP-1RA use. RESULTS: Among 49,987 patients (4,269 GLP-1RA users, 45,718 nonusers), GLP-1RA use was associated with increased odds of inadequate bowel preparation (odds ratio [OR] 1.23, 95% confidence interval [CI] 1.04–1.46). No significant difference in SSP and adenoma detection was observed. In subgroup analysis, GLP-1RA users with diabetes had the highest odds of inadequate preparation (OR 1.88, 95% CI 1.59–2.24) and the lowest odds of SSP detection (OR 0.71, 95% CI 0.57–0.89). DISCUSSION: GLP-1RA use, particularly among patients with diabetes, is associated with higher odds of inadequate bowel preparation and lower SSP detection, whereas adenoma detection was unaffected. Tailored bowel-prep protocols for GLP-1RA users with diabetes should be evaluated prospectively.